Intec Pharma makes amendment to advanced parkinson's patient's study
Tuesday, November 08, 2016
Intec Pharma announces protocol amendment to phase iii study of accordion pill carbidopa/levodopa in advanced parkinson's disease patients.
Says amendment was submitted to and reviewed by U.S. FDA and agency had no comments to these proposed changes.
To advance our phase iii accordance study with protocol amendment to enable a significant reduction in sample size. Expect to complete patient enrollment of study in q4 of 2017.
Source : reuters.com
